

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for inducing ~~a protective~~ an antigen specific systemic and rectal mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a rectal mucosal tissue of the subject with a composition comprising a ~~purified-soluble-antigen~~ chimeric peptide having the amino acid sequence KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9).

2. (Cancelled)

3. (Original) The method of claim 1, wherein said composition further comprises an adjuvant.

4. (Currently amended) The method of claim 3, wherein the adjuvant is ~~selected from~~ cholera toxin (CT), mutant cholera toxin (MCT), or mutant- E. coli heat labile enterotoxin (MLT).

5. (Original) The method of claim 1, further comprising administering a purified cytokine to the subject.

6. (Currently amended) The method of claim ~~[[4]]~~ 5, wherein the cytokine is contacted with a mucosal surface of the subject.

7. (Currently amended) The method of claim 5, wherein the purified cytokine is ~~selected from~~ granulocyte-macrophage colony-stimulating factor (GM-CSF),

interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

8. (Original) The method of claim 1, further comprising administering purified interferon- γ to the subject.

9. (Original) The method of claim 8, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

10. (Original) The method of claim 5, further comprising administering purified interferon- γ to the subject.

11. (Original) The method of claim 10, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

12. (Currently amended) The method of claim 1, wherein said composition further comprises a purified cytokine ~~selected from~~ , wherein the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

13. (Original) The method of claim 1, wherein said composition further comprises purified interferon- γ .

14. (Original) The method of claim 12, wherein said composition further comprises purified interferon- γ .

15. - 24. (Cancelled)

25. (Currently amended) A method for inducing ~~a protective~~ an antigen specific systemic and rectal mucosal CTL response in a mammalian subject, comprising contacting a rectal mucosal tissue of the subject with a composition comprising a ~~soluble antigen~~ chimeric peptide having the amino acid sequence KQIINMWQEVGKAMYAPPISGQIRRIHIGP GRAFYTTKN (SEQ ID NO:9), wherein said composition does not comprise an adjuvant.

26. (Original) The method of claim 25, further comprising administering a purified cytokine to the subject.

27. (Currently amended) The method of claim ~~25~~ 26, wherein the cytokine is contacted with a mucosal surface of the subject.

28. (Currently amended) The method of claim 27, wherein the purified cytokine is ~~selected from~~ granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

29. (Original) The method of claim 25, further comprising administering purified interferon- γ to the subject.

30. (Original) The method of claim 29, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

31. (Original) The method of claim 26, further comprising administering purified interferon- γ to the subject.

32. (Original) The method of claim 31, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

33. (Currently amended) The method of claim 25, wherein said composition further comprises a purified cytokine ~~selected from~~; wherein the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

34. (Original) The method of claim 25, wherein said composition further comprises purified interferon- γ .

35. (Original) The method of claim 33, wherein said composition further comprises purified interferon- γ .

36. - 69. (Cancelled)